Phenix

Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Monday, May 16, 2022 - 9:15pm

BEDFORD, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the first quarter ended March 31, 2022, and highlighted recent accomplishments.

Key Points: 
  • During the first quarter of 2022, we took additional steps to pave the way for Homologys success, said Arthur Tzianabos, Ph.D., Chief Executive Officer of Homology Medicines.
  • Collaboration revenues for the quarter ended March 31, 2022 were $0.8 million, compared to $29.3 million for the quarter ended March 31, 2021.
  • Research and development expenses for the quarter ended March 31, 2022 were $24.3 million, compared to $21.8 million for the quarter ended March 31, 2021.
  • General and administrative expenses for the quarter ended March 31, 2022 were $14.1 million, compared to $8.7 million for the quarter ended March 31, 2021.

FIXX 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys Before May 24th Deadline in Securities Class Action

Retrieved on: 
Saturday, May 14, 2022 - 3:49pm

Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.

Key Points: 
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding Homology Medicines should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vertiv, Homology, Volta, and Embark and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, May 14, 2022 - 2:00am

For more information on the Vertiv class action go to: https://bespc.com/cases/VRT

Key Points: 
  • For more information on the Vertiv class action go to: https://bespc.com/cases/VRT
    Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • For more information on the Embark class action go to: https://bespc.com/cases/EMBK
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vertiv, Homology, Volta, and Embark and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, May 14, 2022 - 2:00am

For more information on the Vertiv class action go to: https://bespc.com/cases/VRT

Key Points: 
  • For more information on the Vertiv class action go to: https://bespc.com/cases/VRT
    Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • For more information on the Embark class action go to: https://bespc.com/cases/EMBK
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Homology Medicines, Inc. (NASDAQ: FIXX)

Retrieved on: 
Tuesday, May 10, 2022 - 6:35am

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.
  • Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, May 24th Deadline Approaching in Securities Class Action

Retrieved on: 
Monday, May 9, 2022 - 5:44pm

SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FAT, Cano, Vertiv, and Homology and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, May 9, 2022 - 2:00am

The class action focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Key Points: 
  • The class action focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • FAT Brands is the subject of a report published by the Los Angeles Times on February 19, 2022.
  • On this news, FAT Brands' stock fell $2.42, or 22.9%, to close at $8.14 per share on February 22, 2022, thereby injuring investors.
  • For more information on the Homology class action go to: https://bespc.com/cases/FIXX
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FAT, Cano, Vertiv, and Homology and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, May 3, 2022 - 2:00am

The class action focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Key Points: 
  • The class action focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • FAT Brands is the subject of a report published by the Los Angeles Times on February 19, 2022.
  • On this news, FAT Brands' stock fell $2.42, or 22.9%, to close at $8.14 per share on February 22, 2022, thereby injuring investors.
  • For more information on the Homology class action go to: https://bespc.com/cases/FIXX
    About Bragar Eagel & Squire, P.C.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on: 
Monday, May 2, 2022 - 9:34pm

Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.

Key Points: 
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding Homology Medicines should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Thursday, April 28, 2022 - 6:07pm

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.